Key result
Disease modifying therapies significantly reduced the risk of short-term disability progression compared to placebo in patients with relapsing-remitting multiple sclerosis.
Why the study?
Multiple meta-analyses evaluating disease modifying therapies for MS progression often reach differing conclusions, requiring contextualisation and identification of methodological differences.
Do disease modifying therapies (DMT) reduce accumulated disability progression in people living with multiple sclerosis?
Systematic Review
Do disease modifying therapies (DMT) reduce accumulated disability progression in people living with multiple sclerosis?
While DMTs improve short-term disability progression in relapsing-remitting MS, translating these findings into clinical practice requires greater methodological consistency in meta-analyses and more head-to-head trials.
Answers are grounded in this paper and cite their sources.
Supports DMT use for short-term RRMS disability; methodological inconsistencies across meta-analyses leave optimal long-term strategies open.
Background: Disease modifying therapy (DMT) efficacy trials make an essential contribution to the development of evidence-based clinical treatments and practices for people with multiple sclerosis (MS). Meta-analysis is a critical part of this process and provides a powerful tool to assess the effects of DMT on MS progression. However, although there have been several meta-analyses on the effect of DMT on MS disease progression, they often do not reach the same conclusions. Objective: Our aim was to better understand and contextualise the results of meta-analyses evaluating DMT, identify differences in methodology that might explain their differing conclusions, and highlight areas for future research that will improve our ability to develop clinical recommendations. Methods: We conducted an overview of systematic reviews with meta-analyses assessing the efficacy of DMT on disability progression in people with MS in PubMed (Medline) and the Cochrane Database of Systematic Reviews. Results: We included 22 meta-analyses in this overview: eight general (on >3 DMT), 11 specific (on ≤3 DMT), 2 that evaluated subsets, and 1 that evaluated long-term effects. We found that there is good evidence that DMT improve short-term (≤2-3 years) disability progression outcomes relative to placebo in people with relapsing-remitting MS. However, results varied substantially between meta-analyses, and there is little evidence of their efficacy in other populations or over longer periods. The relative effects of individual DMT also remain unclear. The variance in results between meta-analyses may be related to the substantial differences in inclusion criteria, which was reflected in the limited overlap in included studies, as well as the year of meta-analysis publication. Of the 123 total unique studies included in the general meta-analyses, 77 (62.6%) were included in only one meta-analysis. This incongruence was also evident in the included DMT. Six of the 16 (37.5%) DMT evaluated in the general meta-analyses were only included in one meta-analysis. Conclusions: Translating DMT efficacy studies into evidence-based clinical practice requires greater methodological consistency in meta-analyses, more data on the relative effects of DMT through head-to-head clinical trials, and better reporting of adverse events.
No takes yet. Share an insight, caveat, or question.
Claflin et al. (2019) conducted a systematic review in Multiple Sclerosis. Disease Modifying Therapies (DMT) vs. Placebo or another DMT was evaluated on Disability progression (RR 0.72, 95% CI 0.66-0.79, p=<0.001). Disease modifying therapies significantly reduced the risk of short-term disability progression compared to placebo in patients with relapsing-remitting multiple sclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: